Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Restylane is a comprehensive line of injectable dermal fillers composed of hyaluronic acid, a naturally occurring polysaccharide that provides structural support and hydration to the skin. Originally developed by the Swedish biotechnology company Q-Med (now a subsidiary of Galderma), Restylane was the first stabilized hyaluronic acid filler to receive FDA approval in 2003. The product line utilizes two primary manufacturing technologies: **NASHA** (Non-Animal Stabilized Hyaluronic Acid), which creates a firmer gel for precision lifting and contouring, and **XpresHAn Technology** (also known as Optimal Balance Technology), which produces a more flexible gel designed for natural-looking results in dynamic areas of the face. Restylane is indicated for the correction of moderate-to-severe facial wrinkles and folds (such as nasolabial folds), lip augmentation, cheek enhancement, and the restoration of volume in the midface and back of the hands.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Restylane.